<DOC>
	<DOCNO>NCT02245516</DOCNO>
	<brief_summary>The primary objective study evaluate safety effect KPI-121 0.25 % ophthalmic suspension KPI-121 1.0 % ophthalmic suspension intraretinal subretinal fluid secondary Retinal Vein Occlusion Diabetic Macular Edema .</brief_summary>
	<brief_title>Exploratory Study KPI-121 Effect Intra- Subretinal Fluid Due Retinal Vein Occlusion/Diabetic Macular Edema</brief_title>
	<detailed_description>This multicenter , randomize , single-masked study evaluate safety effect topical ocular administration either KPI-121 0.25 % ophthalmic suspension KPI-121 1.0 % ophthalmic suspension subject intraretinal subretinal fluid secondary Retinal Vein Occlusion Diabetic Macular Edema .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Have document presence intraretinal subretinal fluid secondary Retinal Vein Occlusion Diabetic Macular Edema Screening Treatment topical , intravitreal injection , posterior subTenon 's , periocular corticosteroid within 120 day prior Visit 1 duration study History uncontrolled glaucoma , IOP 21 mmHg Visit 1 , treat glaucoma study eye Any significant ocular disease could compromise vision study eye ( include ongoing ocular infection , wet agerelated macular degeneration , myopic degeneration active subfoveal choroidal neovascularization ) Known hypersensitivity contraindication investigational product ( ) component Diagnosis severe/serious ocular condition judgment Investigator could confound study assessment limit compliance ; severe/serious systemic disease uncontrolled medical condition judgment Investigator could confound study assessment limit compliance Exposed investigational drug within 30 day prior Visit 1 duration study In opinion Investigator study coordinator , unwillingness inability comply study protocol inability successfully instill eye drop</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Intraretinal Fluid</keyword>
	<keyword>Subretinal Fluid</keyword>
	<keyword>Retinal Vein Occlusion</keyword>
	<keyword>Diabetic Macular Edema</keyword>
</DOC>